Calico(CRC)
Focus: Calico is a publicly-traded biotechnology company headquartered in Long Beach, CA, focused on aging-related treatments across oncology, cardiovascular, and infectious disease indications. The company generated $2.8B in revenue in FY 2025 with $564M net income, positioning it as a revenue-generating biotech with significant R&D ambitions.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
20+2 this month
Stable — net +2 jobs in 30d
6 added, 4 removed. Backfill posture.
Should You Work at Calico?
AI assessmentBest suited for early-career scientists and clinical developers seeking stable, well-capitalized R&D exposure to aging biology without imminent product launch pressure, but with limited near-term career visibility.
Why Work Here
- Public company with stable $2.8B revenue and positive profitability ($564M net income FY 2025), providing career security and investment in R&D infrastructure.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$2.8B
Pipeline & Clinical Trials
DRUG: ABBV-CLS-484
Advanced Solid Tumor CancerClinical Trials (1)
NCT06188975Expanded Access to ABBV-CLS-484
N/AHelp build intelligence for Calico
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.